US › Healthcare

Cartesian Therapeutics Inc. (RNAC)

US · Healthcare · Biotechnology

$6.27-4.71%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$13.7M

Profit YoY

-13.6%

EPS

$0.46

EPS estimate

$-0.83

EPS came in at 0.46 against a street estimate of -0.83 — a beat of 155.4%.

Key statistics

Market cap

$198.8M

Forward P/E

25.1

P/B

31.26

Book value

$-4.17

EPS (TTM)

$-5.78

52-week high

$11.00

52-week low

$5.60

50-day MA

$8.40

200-day MA

$7.70

Beta

0.72

Analyst view

Analysts rate Cartesian Therapeutics Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $33.67.

Shareholding

Insiders

52.13%

Institutions

29.45%

Largest institutional holders

Fund	Stake
Squarepoint Ops LLC	7.45%
BlackRock Inc	2.71%
Vanguard Capital Management, LLC	1.84%
FMR Inc	1.22%
Geode Capital Management, LLC	1.18%
AQR Capital Management LLC	1.18%
683 Capital Management LLC	1.09%
Millennium Management LLC	1.02%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cartesian Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.